Anne M Neilan, MD MPH, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 14 | 2021 | 17275 | 1.230 |
Why?
|
HIV | 3 | 2020 | 1581 | 0.900 |
Why?
|
Death, Sudden, Cardiac | 2 | 2019 | 1554 | 0.720 |
Why?
|
HIV Long-Term Survivors | 1 | 2019 | 121 | 0.610 |
Why?
|
CD4 Lymphocyte Count | 5 | 2021 | 2569 | 0.550 |
Why?
|
Heart Failure | 5 | 2020 | 11593 | 0.520 |
Why?
|
Vascular Grafting | 1 | 2017 | 152 | 0.510 |
Why?
|
Protease Inhibitors | 1 | 2018 | 754 | 0.480 |
Why?
|
Viremia | 1 | 2017 | 706 | 0.460 |
Why?
|
Cost-Benefit Analysis | 5 | 2021 | 5484 | 0.420 |
Why?
|
Fibrosis | 1 | 2020 | 2038 | 0.420 |
Why?
|
Quality-Adjusted Life Years | 4 | 2021 | 1722 | 0.420 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1895 | 0.420 |
Why?
|
Aging | 2 | 2020 | 8650 | 0.370 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 839 | 0.370 |
Why?
|
Ischemia | 1 | 2017 | 1863 | 0.310 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2017 | 2197 | 0.310 |
Why?
|
Patient Readmission | 2 | 2019 | 3261 | 0.290 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1996 | 0.280 |
Why?
|
Myocardium | 1 | 2020 | 4690 | 0.280 |
Why?
|
Viral Load | 4 | 2020 | 3321 | 0.270 |
Why?
|
Peripheral Arterial Disease | 1 | 2017 | 1246 | 0.260 |
Why?
|
Computer Simulation | 2 | 2017 | 6201 | 0.240 |
Why?
|
Endovascular Procedures | 1 | 2017 | 2139 | 0.220 |
Why?
|
Anti-HIV Agents | 4 | 2020 | 4504 | 0.220 |
Why?
|
Mass Screening | 1 | 2018 | 5427 | 0.200 |
Why?
|
Incidence | 5 | 2020 | 21272 | 0.190 |
Why?
|
Anti-Retroviral Agents | 2 | 2020 | 1780 | 0.180 |
Why?
|
Adolescent | 10 | 2022 | 87892 | 0.170 |
Why?
|
Tissue and Organ Procurement | 1 | 2007 | 943 | 0.160 |
Why?
|
Young Adult | 8 | 2022 | 58808 | 0.150 |
Why?
|
Cause of Death | 2 | 2019 | 3675 | 0.150 |
Why?
|
United States | 7 | 2021 | 72136 | 0.140 |
Why?
|
Tissue Donors | 1 | 2007 | 2311 | 0.140 |
Why?
|
Homosexuality, Male | 2 | 2021 | 1329 | 0.130 |
Why?
|
Stroke Volume | 2 | 2020 | 5460 | 0.130 |
Why?
|
Cerebrospinal Fluid | 1 | 2018 | 544 | 0.130 |
Why?
|
Specimen Handling | 1 | 2020 | 707 | 0.130 |
Why?
|
Retreatment | 1 | 2017 | 596 | 0.130 |
Why?
|
Laboratories | 1 | 2009 | 460 | 0.130 |
Why?
|
Decision Trees | 1 | 2017 | 504 | 0.130 |
Why?
|
Cocaine-Related Disorders | 1 | 2019 | 461 | 0.130 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 520 | 0.120 |
Why?
|
Humans | 21 | 2022 | 758406 | 0.120 |
Why?
|
Risk Factors | 5 | 2019 | 73809 | 0.110 |
Why?
|
Markov Chains | 1 | 2017 | 965 | 0.110 |
Why?
|
Male | 13 | 2021 | 358747 | 0.110 |
Why?
|
Female | 13 | 2020 | 390323 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4839 | 0.100 |
Why?
|
Massachusetts | 2 | 2022 | 8823 | 0.100 |
Why?
|
Kidney Transplantation | 1 | 2007 | 4217 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1704 | 0.100 |
Why?
|
Adult | 7 | 2022 | 219935 | 0.100 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2009 | 930 | 0.090 |
Why?
|
Child | 7 | 2022 | 79818 | 0.090 |
Why?
|
Hospitalization | 3 | 2020 | 10652 | 0.090 |
Why?
|
Middle Aged | 6 | 2020 | 219568 | 0.090 |
Why?
|
Metabolomics | 1 | 2018 | 1629 | 0.080 |
Why?
|
Infant, Newborn | 4 | 2022 | 26183 | 0.080 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1487 | 0.080 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2018 | 3759 | 0.080 |
Why?
|
Medication Adherence | 1 | 2020 | 2155 | 0.080 |
Why?
|
Child, Preschool | 5 | 2022 | 42062 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1944 | 0.080 |
Why?
|
Peptide Fragments | 1 | 2020 | 5098 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3858 | 0.070 |
Why?
|
Infant | 4 | 2022 | 36055 | 0.070 |
Why?
|
Pandemics | 3 | 2022 | 8611 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2886 | 0.070 |
Why?
|
Heart | 1 | 2020 | 4382 | 0.070 |
Why?
|
Comorbidity | 2 | 2020 | 10495 | 0.070 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39059 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2019 | 80168 | 0.060 |
Why?
|
Stents | 1 | 2017 | 3162 | 0.060 |
Why?
|
Marketing | 1 | 2007 | 220 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 6157 | 0.060 |
Why?
|
Critical Illness | 1 | 2017 | 2703 | 0.060 |
Why?
|
Iran | 1 | 2007 | 737 | 0.060 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
HIV-1 | 1 | 2020 | 6850 | 0.050 |
Why?
|
Aged | 3 | 2020 | 168218 | 0.050 |
Why?
|
Treatment Outcome | 2 | 2018 | 64378 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15225 | 0.050 |
Why?
|
Africa, Southern | 1 | 2020 | 59 | 0.050 |
Why?
|
Central America | 1 | 2020 | 65 | 0.050 |
Why?
|
South America | 1 | 2020 | 180 | 0.040 |
Why?
|
Caribbean Region | 1 | 2020 | 191 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25956 | 0.040 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6362 | 0.040 |
Why?
|
Asia | 1 | 2020 | 616 | 0.040 |
Why?
|
Cohort Studies | 2 | 2020 | 41256 | 0.040 |
Why?
|
Prognosis | 1 | 2018 | 29557 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2020 | 987 | 0.040 |
Why?
|
Risk Assessment | 1 | 2017 | 23884 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 39872 | 0.030 |
Why?
|
Prospective Studies | 1 | 2020 | 54137 | 0.030 |
Why?
|
Fetal Development | 1 | 2020 | 766 | 0.030 |
Why?
|
World Health Organization | 1 | 2020 | 1312 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15399 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2009 | 1945 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36284 | 0.030 |
Why?
|
Central Nervous System | 1 | 2018 | 1333 | 0.020 |
Why?
|
Life Expectancy | 1 | 2017 | 1244 | 0.020 |
Why?
|
Health Policy | 1 | 2017 | 2677 | 0.020 |
Why?
|
Age Factors | 1 | 2020 | 18358 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15785 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 13285 | 0.010 |
Why?
|